BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified
Introduction: B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular f...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JCDR Research and Publications Private Limited
2016-12-01
|
| Series: | Journal of Clinical and Diagnostic Research |
| Subjects: | |
| Online Access: | https://jcdr.net/articles/PDF/8985/22796_CE[Ra1]_F(GH)_PF1(AH_RK)_PFA(AK)_PF2(PAG).pdf |
| _version_ | 1818301999458811904 |
|---|---|
| author | Eman Badr Eman Masoud Asmaa Gaber Abdou Marwa Serag Eldien |
| author_facet | Eman Badr Eman Masoud Asmaa Gaber Abdou Marwa Serag Eldien |
| author_sort | Eman Badr |
| collection | DOAJ |
| description | Introduction: B-Cell Lymphoma 6 (BCL6) has an oncogenic role
in tumourigenesis of various malignancies. It represses genes
involved in terminal differentiation and plays complementary
role with Signal Transducer and Activator of Transcription 3
(STAT3) in triple-negative breast cancer cellular function.
Aim: To evaluate the expression of BCL6 in cancer breast and
determine its correlation with the clinico-pathological features
including the molecular subtype of breast carcinoma.
Materials and Methods: This prospective case control study
was carried out on 150 patients, divided into 100 cases of
invasive duct carcinoma not otherwise specified and 50 benign
breast lesions including fibroadenoma and fibrocystic disease.
Fresh tissues were excised, which were then subjected to RNA
extraction. The BCL6 mRNA level was assessed using real-time
reverse transcription Polymerase Chain Reaction (PCR).
Results: There was a significant higher levels of BCL6 mRNA in
malignant cases compared to benign ones (p<0.001). The level
of BCL6 mRNA was higher in cases showing advanced tumor
stage (p<0.04), triple negative subtype and associated in situ
component (p<0.001) compared to cases with an early stage,
luminal or Her 2-neu positive subtypes and those lacking in situ
component.
Conclusion: BCL6 is up-regulated in breast cancer and is
associated with poor prognostic features such as advanced
stage and triple negative molecular subtype. BCL6 inhibitors
might be considered as targeted therapy for breast cancer. |
| first_indexed | 2024-12-13T05:31:56Z |
| format | Article |
| id | doaj.art-bf6d01cb135744ddb5f55e6c607099b1 |
| institution | Directory Open Access Journal |
| issn | 2249-782X 0973-709X |
| language | English |
| last_indexed | 2024-12-13T05:31:56Z |
| publishDate | 2016-12-01 |
| publisher | JCDR Research and Publications Private Limited |
| record_format | Article |
| series | Journal of Clinical and Diagnostic Research |
| spelling | doaj.art-bf6d01cb135744ddb5f55e6c607099b12022-12-21T23:58:02ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2016-12-011012XC01XC0410.7860/JCDR/2016/22796.8985BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise SpecifiedEman Badr0Eman Masoud1 Asmaa Gaber Abdou2Marwa Serag Eldien3Assistant Professor, Department of Biochemistry, Shebein Elkom, Menoufia, Egypt.Lecturer, Department of Biochemistry, Shebein Elkom, Menoufia, Egypt.Professor, Department of Pathology, Shebein Elkom, Menoufia, Egypt.Lecturer, Department of Pathology, Shebein Elkom, Menoufia, Egypt.Introduction: B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular function. Aim: To evaluate the expression of BCL6 in cancer breast and determine its correlation with the clinico-pathological features including the molecular subtype of breast carcinoma. Materials and Methods: This prospective case control study was carried out on 150 patients, divided into 100 cases of invasive duct carcinoma not otherwise specified and 50 benign breast lesions including fibroadenoma and fibrocystic disease. Fresh tissues were excised, which were then subjected to RNA extraction. The BCL6 mRNA level was assessed using real-time reverse transcription Polymerase Chain Reaction (PCR). Results: There was a significant higher levels of BCL6 mRNA in malignant cases compared to benign ones (p<0.001). The level of BCL6 mRNA was higher in cases showing advanced tumor stage (p<0.04), triple negative subtype and associated in situ component (p<0.001) compared to cases with an early stage, luminal or Her 2-neu positive subtypes and those lacking in situ component. Conclusion: BCL6 is up-regulated in breast cancer and is associated with poor prognostic features such as advanced stage and triple negative molecular subtype. BCL6 inhibitors might be considered as targeted therapy for breast cancer.https://jcdr.net/articles/PDF/8985/22796_CE[Ra1]_F(GH)_PF1(AH_RK)_PFA(AK)_PF2(PAG).pdfbreast cancerpolymerase chain reactiontarget therapystagetriple negative |
| spellingShingle | Eman Badr Eman Masoud Asmaa Gaber Abdou Marwa Serag Eldien BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified Journal of Clinical and Diagnostic Research breast cancer polymerase chain reaction target therapy stage triple negative |
| title | BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified |
| title_full | BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified |
| title_fullStr | BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified |
| title_full_unstemmed | BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified |
| title_short | BCL6 mRNA Expression Level in Invasive Duct Carcinoma not otherwise Specified |
| title_sort | bcl6 mrna expression level in invasive duct carcinoma not otherwise specified |
| topic | breast cancer polymerase chain reaction target therapy stage triple negative |
| url | https://jcdr.net/articles/PDF/8985/22796_CE[Ra1]_F(GH)_PF1(AH_RK)_PFA(AK)_PF2(PAG).pdf |
| work_keys_str_mv | AT emanbadr bcl6mrnaexpressionlevelininvasiveductcarcinomanototherwisespecified AT emanmasoud bcl6mrnaexpressionlevelininvasiveductcarcinomanototherwisespecified AT asmaagaberabdou bcl6mrnaexpressionlevelininvasiveductcarcinomanototherwisespecified AT marwaserageldien bcl6mrnaexpressionlevelininvasiveductcarcinomanototherwisespecified |